<?xml encoding="utf-8" ?> Novartis AG NVS stock climbed Tuesday after the Swiss drugmaker reported positive Phase 3 results for remibrutinib in relapsing multiple sclerosis. Remibrutinib Meets Primary ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that ...

Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances its lead drug candidate vidofludimus calcium through late-stage development in ...

The FDA has authorized the launch of an early-stage trial testing a CAR T-cell therapy for people with hard-to-treat ...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluating intranasal foralumab in patients with ...

ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was submitting its experimental multiple ‌sclerosis drug fenebrutinib to global regulators after meeting late-stage trial goals ...

European drug regulators have given a positive review to an experimental multiple sclerosis treatment from Sanofi that the Food and Drug Administration rejected earlier this year, positioning the ...

A combination of metformin, a common diabetes drug, and clemastine, an antihistamine, can help repair myelin—the protective coating around nerves, which gets damaged in multiple sclerosis (MS) causing ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

The FDA recently approved the first drug for the treatment of relapsing forms of multiple sclerosis (MS). The announcement marks a significant achievement, which is expected to help the 400,000 MS ...

When Jean Kay started a brand-new multiple sclerosis treatment called Rebif in 2003, it cost $17,500 a year. That was pricey, but her insurance covered most of it, and the drug slowed the disease’s ...

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...